These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8825290)

  • 1. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.
    Manickan E; Yu Z; Rouse RJ; Wire WS; Rouse BT
    Viral Immunol; 1995; 8(2):53-61. PubMed ID: 8825290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
    Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
    Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.
    Banks TA; Jenkins FJ; Kanangat S; Nair S; Dasgupta S; Foster CM; Rouse BT
    Virology; 1994 Apr; 200(1):236-45. PubMed ID: 8128625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
    Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
    Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0.
    Martin S; Zhu XX; Silverstein SJ; Courtney RJ; Yao F; Jenkins FJ; Rouse BT
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2391-9. PubMed ID: 2172452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H; Hoeller D; Yao F
    J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.
    Manickan E; Francotte M; Kuklin N; Dewerchin M; Molitor C; Gheysen D; Slaoui M; Rouse BT
    J Virol; 1995 Aug; 69(8):4711-6. PubMed ID: 7609036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.
    Brehm MA; Bonneau RH; Knipe DM; Tevethia SS
    J Virol; 1997 May; 71(5):3534-44. PubMed ID: 9094625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
    Frye TD; Chiou HC; Hull BE; Bigley NJ
    Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
    Sin JI; Kim JJ; Zhang D; Weiner DB
    Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
    Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
    Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection.
    Nass PH; Elkins KL; Weir JP
    Vaccine; 2001 Jan; 19(11-12):1538-46. PubMed ID: 11163680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant.
    Zhu M; Xu X; Liu H; Liu X; Wang S; Dong F; Yang B; Song G
    J Med Microbiol; 2003 Mar; 52(Pt 3):223-228. PubMed ID: 12621087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.